Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for diabetic macular edema: contrast sensitivity, BCVA, and foveal microstructure
jRCTs031180161Completed
- Sponsor
- Bayer
- Start
- Jun 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Primary endpoint: Contrast sensitivity change at 12 months. Started Jun 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCTs031180161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180161.